FDA Determines Regulatory Review Period for LAZCLUZE Patent Extension

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of LAZCLUZE, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).